Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
02/2011
02/23/2011CN101632666B Drug composition used for treating high blood pressure
02/23/2011CN101574323B Migltol microcapsule tablet and preparation method thereof
02/23/2011CN101317972B Yilongbao soft capsule and preparation thereof
02/23/2011CN101219120B Telmisartan dispersible tablet and method for preparing the same
02/23/2011CN101142214B Ocaperidone salts and pharmaceutical compositions containing the same
02/23/2011CN101133064B Substituted oxa-diaza-spiro-[5.5]-undecanone derivatives and their use as neurokinin antagonists
02/23/2011CN101035770B Novel 2-amino-quinazoline derivatives useful as inhibitors of beta-secretase ( BACE )
02/22/2011USRE42164 Hepatitis C inhibitor tri-peptides
02/22/2011US7894769 Wireless microphone communication system
02/22/2011US7893304 Hydroquinone long-chain derivatives and/or phenoxy long-chain derivatives, and pharmaceuticals comprising the same
02/22/2011US7893297 Amorphous sodium 4-[4-chloro-2-hydroxybenzoyl)amino]butanoate
02/22/2011US7893292 Merocyanine derivatives for cosmetic use
02/22/2011US7893291 Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
02/22/2011US7893289 Adamantanamines and neramexane salts of thiomolybdic and thiotungstic acids
02/22/2011US7893285 Transdermal compositions
02/22/2011US7893284 Oestrogen derivatives as inhibitors of steroid sulphatase
02/22/2011US7893282 7-substituted fused ring tetracycline compounds
02/22/2011US7893280 2,4-disubstituted thiazolyl derivatives
02/22/2011US7893278 Antiproliferative agents; antitumor agents; anticancer agents
02/22/2011US7893272 Reagents and kits for detection of influenza virus and the like
02/22/2011US7893271 Benzimidazole carbamates and (thio) carbamates, and the synthesis and use thereof
02/22/2011US7893267 Benzazole derivatives, compositions, and methods of use as β-secretase inhibitors
02/22/2011US7893266 Detection of cancer cells in vitro using sigma-2 receptor ligands as radiotracers
02/22/2011US7893261 bi-functional organic molecules which combine serotonin transporter reuptake inhibition with serotonin (5-HT, such as 5-HT2A) receptor antagonism in one molecular entity
02/22/2011US7893259 Pyrido-pyrimidine derivatives, preparation thereof, and therapeutic use thereof
02/22/2011US7893256 Azabicycloalkane compounds
02/22/2011US7893252 Selectively depolymerized galactomannan polysaccharide
02/22/2011US7893247 siRNA targeting spleen tyrosine kinase
02/22/2011US7893246 Sirna capable of inhibiting the expression of an oncogene involved in cervical cancer
02/22/2011US7893245 Interfering RNA molecules
02/22/2011US7893242 Oligonucleotide compositions and their use to induce apoptosis
02/22/2011US7893226 Use of lipid conjugates in the treatment of diseases
02/22/2011US7893204 Attractin/mahogany-like polypeptides
02/22/2011US7893113 Materials and methods for modulating metabolism
02/22/2011US7893112 N-(1-cyanocyclopropyl)-4,4-difluoro-2(S)-[2,2,2-trifluoro-1(S)-(4-fluorophenyl)ethylamino)octamide; rheumatoid arthritis, multiple sclerosis, myasthenia gravis, psoriasis, pemphigus vulgaris, Graves' disease, myasthenia gravis, lupus, asthma, pain, atherosclerosis; cathepsins B, K, L, F, and S inhibitors
02/22/2011US7893111 Process for enantioselective synthesis of single enantiomers of thio-substituted arylmethanesulfinyl derivatives by asymmetric oxidation
02/22/2011US7893110 Carboxylic acid amides provoking a cooling sensation
02/22/2011US7893109 N,N-dihalogenated amino acids and derivatives
02/22/2011US7893108 Antiviral methods and compositions
02/22/2011US7893107 Therapeutic methods using prostaglandin EP4 agonist components
02/22/2011US7893106 Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same
02/22/2011US7893105 Levodopa prodrug mesylate, compositions thereof, and uses thereof
02/22/2011US7893104 Process for synthesizing silver-silica particles and applications
02/22/2011US7893102 Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses
02/22/2011US7893101 Reducing tumor necrosis factor, phosphodiesterase inhibitor; anticancer agents; leukemia; antidepressants; antiinflammatory agents; respiratory system disorders
02/22/2011US7893100 carvedilol phosphate salts, which include novel crystalline forms of carvedilol dihydrogen phosphate (i.e., dihydrogen phosphate salt of 1-(carbazol-4-yloxy-3-[[2-(o-methoxyphenoxy) ethyl]amino]-2-propanol) and/or carvedilol hydrogen phosphate, etc.), and/or solvates , compositions containing compounds
02/22/2011US7893099 Cyclopentane derivatives
02/22/2011US7893098 Pyrrole and pyrazole DAAO inhibitors
02/22/2011US7893097 Methods and compositions for increasing solubility of azole drug compounds that are poorly soluble in water
02/22/2011US7893096 For example, N-methyl-4-[(2-{[2-(1-methylethyl)phenyl]amino}-1 H-benzimidazol-5-yl)oxy]pyridine-2-carboxamide; administering the compounds alone or in combination with another agent for the treatment of cancer, infectious diseases and/or allergies/asthma
02/22/2011US7893095 Treatment or prevention of diseases or conditions associated with vascular endothelium dysfunction or liver injury; 1,4-dimethylpyridinium Chloride; diabetes, metabolic syndrome, atherosclerosis
02/22/2011US7893094 Amphiphilic pyridinium compounds, method of making and use thereof
02/22/2011US7893093 Sulfonyl containing compounds as cysteine protease inhibitors
02/22/2011US7893091 Combination therapy for the treatment of urinary frequency, urinary urgency and urinary incontinence
02/22/2011US7893090 N-aroyl cyclic amine derivatives as orexin receptor antagonists
02/22/2011US7893089 IL-8 receptor antagonists
02/22/2011US7893088 6-substituted isoquinoline derivatives
02/22/2011US7893087 3(R)-1-Phenethyl-(9[H]-xanthene-9-carbonyloxy)-1-azoniabicyclo[2.2.2] octane quaternary salt with a mono- or polyvalent anion; antimuscarinic agents used to treat chronic obstructive pulmonary disease, chronic bronchitis, bronchial hyperreactivity, asthma, or rhinitis
02/22/2011US7893086 Sirtuin modulating compounds
02/22/2011US7893085 3-(4-Bromo-2-fluoro-phenylamino)-thieno[3,2-c]pyridine-2-carboxylic acid (2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-amide; mitogen activated protein extracellular kinase kinase (MEK) inhibitor; antiproliferative, antiinflammatory agent
02/22/2011US7893084 Viral polymerase inhibitors
02/22/2011US7893082 Substituted tetrahydroquinolines
02/22/2011US7893081 Tyrosine kinase inhibitors
02/22/2011US7893080 Method of restoring the incretin effect
02/22/2011US7893079 Substituted monocyclic CGRP receptor antagonists
02/22/2011US7893078 Use of cyclopamine in the treatment of basal cell carcinoma and other tumors
02/22/2011US7893077 Bisaryl-sulfonamides
02/22/2011US7893076 Crystalline form F of the methanesulfonic acid addition salt of Imatinib, 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide; suitable for topical, enteral, for example oral or rectal, or parenteral administration
02/22/2011US7893075 Compounds modulating c-fms and/or c-kit activity and uses therefor
02/22/2011US7893074 inhibition of focal adhesion kinase or/and IGF-1 Receptor; for example: 2-[2-(2,5-Dimethoxy-phenylamino)-5-nitro-pyrimidin-4-ylamino]-N-methyl-benzenesulfonamide
02/22/2011US7893073 Heterocyclic derivatives
02/22/2011US7893072 Trp-p8 active compounds and therapeutic treatment methods
02/22/2011US7893071 Synthesis and evaluation of novel phthalimide mimics as anti-angiogenic
02/22/2011US7893070 Method of treating parturient placental mammals in order to reduce maternal and/or uterine exhaustion
02/22/2011US7893069 Substituted imidazo[2,1-b]thiazole compounds and uses thereof
02/22/2011US7893068 Physiologically active substances
02/22/2011US7893067 Cysteine protease inhibitors
02/22/2011US7893066 N-[2-(6-{[(3,4-dichlorophenyl)methyl]amino}-2-(4-methoxyphenyl)-3-oxo-4-hydropyridino[2,3-b]pyrazin-4-yl)ethyl]acetamide derivatives; antidiabetic agents; abnormal lipid levels, obesity; cardiovascular, skin and metabolic disorders
02/22/2011US7893065 mitogen activated protein kinase inhibitors; 4-(2-Fluoro-4-(methylthio)phenylamino)-N-(2-hydroxyethoxy)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide; used in the treatment of hyperproliferative diseases, such as cancer and inflammation in mammals
02/22/2011US7893064 N-[1-(3-fluoro-benzyl)-1H-indazol-5-yl]-5-[(4-methoxy-phenyl)-hydrazonomethyl]-pyrimidine-4,6-diamine; inhibitors of ATP-protein kinase interactions; antiinflammatory, anticarcinogenic, antidiabetic agent; neurodegenerative diseases
02/22/2011US7893063 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer
02/22/2011US7893062 Pyrrolidine derivatives as dual NK1/NK3 receptor antagonists
02/22/2011US7893061 Alkyne-substituted pyridone compounds and methods of use
02/22/2011US7893060 Thiazolopyrimidines and their use as inhibitors of phosphatidylinositol-3 kinase
02/22/2011US7893059 Thiazolopyrimidine PI3K inhibitor compounds and methods of use
02/22/2011US7893058 Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases
02/22/2011US7893057 Inhibitors of cyclin-dependent kinases, compositions and uses related thereto
02/22/2011US7893056 Peptide deformylase inhibitors
02/22/2011US7893055 HIV integrase inhibitors
02/22/2011US7893054 Materials and methods relating to protein aggregation in neurodegenerative disease
02/22/2011US7893053 Treating psychological conditions using muscarinic receptor M1 antagonists
02/22/2011US7893052 CGRP receptor antagonists
02/22/2011US7893051 Thiophenyl and pyrrolyl azepines as serotonin 5-HT2c receptor ligands and uses thereof
02/22/2011US7893050 Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
02/22/2011US7893049 Thiazolyl-dihydro-indazole
02/22/2011US7893048 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
02/22/2011US7893047 comprising zinc pyrithione, and 4-bromo-2-(4-chlorophenyl)-5-(trifluoromethyl)-1H-pyrrole-3-carbonitrile, present in a weight ratio of 3:2 to 2:3, and wherein biocidal composition is copper free or has low copper content
02/22/2011US7893046 Therapeutic or prophylactic agent for leukemia
02/22/2011US7893044 Composition and method for altering levels of or sensitivity to adenosine with analogs of dehydroepiandrosterone
02/22/2011US7893043 2-methylene-(17Z)-17(20)-dehydro-19,21-dinor-vitamin D analogs